GRAIL Raises $110 Million from Samsung to Advance Galleri in US and Asia
GRAL•GRAIL raised $110 million in equity financing from Samsung C&T and affiliates at $70.05 per share, bolstering its balance sheet and extending cash runway. The investment underpins regulatory approval efforts for its Galleri multi-cancer early detection test in the US and funds planned rollout in South Korea and Asia.
1. Equity Financing and Investment Terms
GRAIL closed a $110 million equity financing with Samsung C&T Corporation and affiliated entities, issuing new common shares at $70.05 per share. Samsung's investment represents a strategic, long-term commitment to support GRAIL's growth objectives.
2. Strengthening Balance Sheet and Approval Efforts
Proceeds from the financing will bolster GRAIL's balance sheet and extend its operational cash runway as the company seeks regulatory approval and reimbursement for its Galleri multi-cancer early detection test in the United States.
3. Asian Market Commercialization Plans
Under the agreement, GRAIL and Samsung C&T will collaborate to commercialize the Galleri test in South Korea, with potential expansion into Japan and Singapore subject to regulatory clearances. Initial testing will remain at GRAIL's North Carolina lab while market deployment plans progress.
